Immunization with recombinant modified vaccina virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques

Journal of General Virology

Volumn 83, Issue 4, 2002, Pages 807-818

  Nilsson, Charlotta ^a   Sutter, Gerd ^a   Walther Jallow, Lilian ^a   ten Haaft, Peter ^a   Åkerblom, Lennart ^a   Heeney, Jonathan ^a   Erfle, Volker ^a   Böttiger, Per ^a   Biberfeld, Gunnel ^a   Thorstensson, Rigmor ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; POL PROTEIN; PROTEIN ANTIBODY; PROTEIN P27; RECOMBINANT PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VACCINIA VACCINE; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE COURSE; ENVELOPE GENE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MACACA; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; PROVOCATION TEST; SIMIAN IMMUNODEFICIENCY VIRUS; STRUCTURAL GENE; SURVIVAL TIME; TIME; VACCINIA VIRUS; VIRUS INFECTION; VIRUS RECOMBINATION;

ANIMALIA; MACACA; RNA VIRUSES; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS;

EID: 0036210830     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-83-4-807     Document Type: Article

References (39)

1. Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys
2. The complete genomic sequence of the modified vaccinia Ankara strain: Comparison with other orthopoxyviruses
3. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques
4. Prime-boost immunization strategies against HIV
5. ISCOMs and other saponin based adjuvants
6. mae251: Dependence on route of challenge exposure
7. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine
8. Developments in preclinical AIDS vaccine efficacy models
9. Compact, synthetic, vaccinia virus early/late promoter for protein expression
10. Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines
11. The prime-boost concept applied to HIV preventive vaccines
12. Envelope glycoproteins of HIV-1, HIV-2, and SIV purified with Galanthus nivalis agglutinin induce strong immune responses
13. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen
14. Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells
15. Immune correlates of protection from HIV and AIDS - More answers but yet more questions
16. A vaccine strategy utilizing a combination of three different chimeric vectors which share specific vaccine antigens
17. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara
18. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-I. A report from the Sydney Blood Bank Cohort
19. The requirements of lipids for the formation of immunostimulating complexes (iscoms)
20. Cell-mediated immunity to low doses of SIV sm in cynomolgus macaques did not confer protection against mucosal rechallenge
21. Human trials of HIV-1 vaccines
22. Protection against monkey-cell grown cell-free HIV-2 challenge in macaques immunized with native HIV-2 envelope glycoprotein gp 125
23. Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara
24. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV
25. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI)
26. The science of AIDS: A tale of two worlds
27. Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp 160 vaccines
28. Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in macaques
29. Live attenuated AIDS vaccines
30. Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope
31. Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression
32. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer
33. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamenstic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge
34. Nonreplicating vaccinia vector efficiently expresses recombinant genes
35. A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques
36. A capture enzyme immunoassay for detection of HIV-2/SIV antigen
37. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in rhesus macaques: Evidence for viral clearance
38. Optimization of polymerase chain reaction for detection of HIV type 2 DNA
39. Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization